Neurocrine Biosciences Inc (NBIX)
Profitability ratios
Return on sales
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Gross profit margin | 50.57% | 45.00% | 47.34% | 56.44% | 53.17% |
| Operating profit margin | 13.32% | 17.64% | 9.25% | 16.39% | 9.56% |
| Pretax margin | 17.63% | 15.15% | 9.15% | 10.73% | 6.15% |
| Net profit margin | 13.26% | 10.95% | 8.09% | 40.95% | 4.89% |
Neurocrine Biosciences, Inc. has shown stable and impressive gross profit margins over the past five years, ranging from 97.90% to 99.06%. This indicates the company's ability to efficiently manage its production costs and generate profits from its core operations.
In terms of operating profit margins, there has been some variability, with the margins ranging from 16.73% to 31.31% during the same period. This suggests fluctuations in the company's operating expenses and overall operational efficiency.
The pretax margins have also shown fluctuations, ranging from 5.91% to 17.60%. This ratio reflects the company's ability to generate profits before accounting for taxes. The variability in this margin could indicate changes in the company's tax burden or other non-operating expenses.
Neurocrine Biosciences, Inc. has shown a significant fluctuation in net profit margins over the past five years, ranging from 4.70% to 38.94%. This variability may be due to factors such as one-time expenses, changes in revenue, or fluctuations in other income and expenses.
Overall, while the company has maintained high gross profit margins, there have been fluctuations in operating, pretax, and net profit margins. Further analysis would be needed to understand the specific factors driving these changes in profitability ratios over time.
Return on investment
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 7.72% | 10.51% | 4.95% | 9.40% | 5.54% |
| Return on assets (ROA) | 7.68% | 6.52% | 4.32% | 23.48% | 2.83% |
| Return on total capital | 15.09% | 12.94% | 7.44% | 9.66% | 7.51% |
| Return on equity (ROE) | 11.19% | 9.05% | 6.52% | 36.17% | 5.81% |
Neurocrine Biosciences, Inc. has demonstrated consistent profitability over the years based on its profitability ratios.
- Operating return on assets (Operating ROA) has shown a positive trend, increasing from 10.03% in 2021 to 12.14% in 2023. This indicates that the company has been effective in generating operating profits relative to its total assets.
- Return on assets (ROA) has fluctuated over the years, with a significant spike to 23.48% in 2020, followed by a decrease in subsequent years. The company's ability to generate profits from its total assets has shown some volatility.
- Return on total capital has also displayed a positive trend, increasing from 12.16% in 2021 to 16.44% in 2023. This ratio highlights the company's efficiency in generating returns from both equity and debt capital.
- Return on equity (ROE) has shown improvement over the years, with a notable increase to 36.17% in 2020. However, the ratio has fluctuated since then but remains positive, indicating the company's ability to generate profits for its shareholders.
Overall, Neurocrine Biosciences, Inc. has shown strong profitability ratios, with improvements in some areas and fluctuations in others. The company's ability to generate returns from its assets, capital, and equity reflects its operational efficiency and financial performance.